Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. BJS 2017; 104: 1443-1450.
Published: 12th September 2017
Authors: C. Palanivelu, P. Senthilnathan, S. C. Sabnis, N. S. Babu, S. Srivatsan Gurumurthy, N. Anand Vijai et al.
Laparoscopic resection as an alternative to open pancreatoduodenectomy may yield short‐term benefits, but has not been investigated in a randomized trial. The aim of this study was to compare laparoscopic and open pancreatoduodenectomy for short‐term outcomes in a randomized trial.
Patients with periampullary cancers were randomized to either laparoscopic or open pancreatoduodenectomy. The outcomes evaluated were hospital stay (primary outcome), and blood loss, radicality of surgery, duration of operation and complication rate (secondary outcomes).
Of 268 patients, 64 who met the eligibility criteria were randomized, 32 to each group. The median duration of postoperative hospital stay was longer for open pancreaticoduodenectomy than for laparoscopy (13 (range 6–30)
Laparoscopy offered a shorter hospital stay than open pancreatoduodenectomy in this randomized trial. Registration number: NCT02081131(
You may also be interested in
Randomized clinical trial
Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection. BJS 2017; 104: 1462-1469.
Authors: S. B. Ellebæk, C. W. Fristrup, C. Hovendal, N. Qvist, L. Bundgaard, S. Salomon et al.
Notes: No additional benefit
Authors: K. J. Roberts
Authors: B. Le Roy, M. Gelli, G. Pittau, M.‐A. Allard, B. Pereira, B. Serji et al.
Notes: Option to increase resectability
Authors: A. J. Klompenhouwer, M. E. E. Bröker, M. G. J. Thomeer, M. P. Gaspersz, R. A. de Man, J. N. M. IJzermans et al.
Notes: Wait and see policy justified
Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. BJS 2017; 104: 1568-1577.
Authors: L. G. M. van der Geest, V. E. P. P. Lemmens, I. H. J. T. de Hingh, C. J. H. M. van Laarhoven, T. L. Bollen, C. Y. Nio et al.
Notes: Negative impacts
Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. BJS 2017; 104: 1539-1548.
Authors: R. Ravikumar, C. Sabin, M. Abu Hilal, A. Al‐Hilli, S. Aroori, G. Bond‐Smith et al.
Notes: No difference between type of reconstruction
Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. BJS 2017; 104: 1558-1567.
Authors: D. Kleive, M. A. Sahakyan, A. E. Berstad, C. S. Verbeke, I. P. Gladhaug, B. Edwin et al.
Notes: Severe complications, more reoperations
Authors: R. Green, S. C. Charman, T. Palser
Notes: Variation in compliance related to outcomes
Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinoma. BJS 2017; 104: 1549-1557.
Authors: T. Maeta, T. Ebata, E. Hayashi, T. Kawahara, S. Mizuno, N. Matsumoto et al.
Notes: Poor survival despite portal vein resection
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma.
Authors: A. Cucchetti, V. Mazzaferro, A. D. Pinna, C. Sposito, R. Golfieri, C. Serra et al.
Notes: Resection is better
Meta‐analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. BJS 2017; 104: 1433-1442.
Authors: S. Erridge, P. H. Pucher, S. R. Markar, G. Malietzis, T. Athanasiou, A. Darzi et al.
Notes: No evidence for best treatment